(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

NCT02039726 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

AML

Interventions

DRUG: Quizartinib
DRUG: Salvage Chemotherapy

Sponsor

Daiichi Sankyo